About
Company Profile
Management Team
Honors Course
Vision & Mission
Chengdu Biostar
Synthetic Biology
R&D
Clinical Recruitment
Pipeline
Partnering
Investor Relations
Product
Utidelone
Medical consultation and Drug Safety Hotline
Contact
Career
Contact
CN
菜单
search
Index
About
Company Profile
Management Team
Honors Course
Vision & Mission
Chengdu Biostar
Synthetic Biology
R&D
Clinical Recruitment
Pipeline
Partnering
Investor Relations
Product
Utidelone
Medical consultation and Drug Safety Hotline
Contact
Career
Contact
news
Company News
all
all
2021
2020
2019
2024-09-03
Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule
2024-07-05
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
2024-03-28
73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
2024-03-21
100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
2023-06-16
FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer
2023-06-12
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)—The World's First Oral Epothilone Anti-Cancer Drug